Similar articles

• Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.

  Farid NA, Kurihara A, Wrighton SA. Farid NA, et al. J Clin Pharmacol. 2010 Feb;50(2):126-42. doi: 10.1177/0091270009343005. Epub 2009 Nov 30. J Clin Pharmacol. 2010. PMID: 19948947 Review.
• Cost is not a barrier to implementing clopidogrel pharmacogenetics.

  Cavallari LH, Schumock GT. Cavallari LH, et al. Pharmacotherapy. 2012 Apr;32(4):299-303. doi: 10.1002/j.1875-9114.2012.01107.x. Pharmacotherapy. 2012. PMID: 22461119 No abstract available.
• Bedside evaluation of thienopyridine antiplatelet therapy.

  Price MJ. Price MJ. Circulation. 2009 May 19;119(19):2625-32. doi: 10.1161/CIRCULATIONAHA.107.696732. Circulation. 2009. PMID: 19451364 Review. No abstract available.
• Intensive antiplatelet therapy for reduction of ischaemic events.

  Ramaraj R. Ramaraj R. Lancet. 2008 Aug 16;372(9638):531; author reply 532. doi: 10.1016/S0140-6736(08)61225-8. Lancet. 2008. PMID: 18707975 No abstract available.
• Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.

  Varenhorst C, James S, Erlinge D, Brandt JT, Braun OO, Man M, Siegbahn A, Walker J, Wallentin L, Winters KJ, Close SL. Varenhorst C, et al. Eur Heart J. 2009 Jul;30(14):1744-52. doi: 10.1093/eurheartj/ehp157. Epub 2009 May 9. Eur Heart J. 2009. PMID: 19429918 Free PMC article. Clinical Trial.